Cargando…
Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in Cancer
Aberrant glycosylation, a common feature associated with malignancy, has been implicated in important events during cancer progression. Our understanding of the role of glycans in cancer has grown exponentially in the last few years, concurrent with important advances in glycomics and glycoproteomic...
Autores principales: | Cagnoni, Alejandro J., Pérez Sáez, Juan M., Rabinovich, Gabriel A., Mariño, Karina V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865499/ https://www.ncbi.nlm.nih.gov/pubmed/27242953 http://dx.doi.org/10.3389/fonc.2016.00109 |
Ejemplares similares
-
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
por: Smith, Benjamin A. H., et al.
Publicado: (2021) -
Terminal Epitope-Dependent Branch Preference of Siglecs Toward N-Glycans
por: Wang, Shuaishuai, et al.
Publicado: (2021) -
Computationally guided conversion of the specificity of E-selectin to mimic that of Siglec-8
por: Wang, Xiaocong, et al.
Publicado: (2022) -
Glycobiology of Eosinophilic Inflammation: Contributions of Siglecs, Glycans, and Other Glycan-Binding Proteins
por: O’Sullivan, Jeremy A., et al.
Publicado: (2017) -
Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology
por: Bannoud, Nadia, et al.
Publicado: (2023)